- Home
- FSHP vs MGX Comparison
FSHP vs MGX Comparison
Compare FSHP & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSHP
- MGX
- Stock Information
- Founded
- FSHP 2018
- MGX 2018
- Country
- FSHP United States
- MGX United States
- Employees
- FSHP N/A
- MGX N/A
- Industry
- FSHP
- MGX
- Sector
- FSHP
- MGX
- Exchange
- FSHP NYSE
- MGX NYSE
- Market Cap
- FSHP 92.2M
- MGX 62.1M
- IPO Year
- FSHP 2024
- MGX 2024
- Fundamental
- Price
- FSHP $10.43
- MGX $1.52
- Analyst Decision
- FSHP
- MGX Strong Buy
- Analyst Count
- FSHP 0
- MGX 4
- Target Price
- FSHP N/A
- MGX $13.00
- AVG Volume (30 Days)
- FSHP 756.0
- MGX 665.7K
- Earning Date
- FSHP 01-01-0001
- MGX 08-13-2025
- Dividend Yield
- FSHP N/A
- MGX N/A
- EPS Growth
- FSHP N/A
- MGX N/A
- EPS
- FSHP 0.21
- MGX N/A
- Revenue
- FSHP N/A
- MGX $45,263,000.00
- Revenue This Year
- FSHP N/A
- MGX N/A
- Revenue Next Year
- FSHP N/A
- MGX $11.75
- P/E Ratio
- FSHP $49.03
- MGX N/A
- Revenue Growth
- FSHP N/A
- MGX N/A
- 52 Week Low
- FSHP $9.99
- MGX $1.23
- 52 Week High
- FSHP $10.48
- MGX $5.50
- Technical
- Relative Strength Index (RSI)
- FSHP N/A
- MGX 47.41
- Support Level
- FSHP N/A
- MGX $1.46
- Resistance Level
- FSHP N/A
- MGX $1.66
- Average True Range (ATR)
- FSHP 0.00
- MGX 0.13
- MACD
- FSHP 0.00
- MGX 0.00
- Stochastic Oscillator
- FSHP 0.00
- MGX 46.30
About FSHP FLAG SHIP ACQUISITION CORPORATION
Flag Ship Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.